The New York-based law firm is currently evaluating three distinct transactions: the $14.25 per share cash sale of Utz Brands to Intersnack Group, the $127.00 per share acquisition of Integer Holdings by KKR, and the merger between Fulcrum Therapeutics and Slate Medicines. Under the terms of the Fulcrum agreement, existing shareholders would retain a 5.0% stake in the combined entity upon completion.

Attorneys at Halper Sadeh are examining whether these agreements include provisions that unfairly limit superior competing offers or provide insiders with financial benefits not available to the general public. The firm, led by Daniel Sadeh and Zachary Halper, indicated it may seek increased compensation or additional disclosures on behalf of investors. Shareholders seeking to review their legal options are being invited to consult with the firm on a contingent fee basis.